Regulatory round-up: 13 July 2026

13 July 2026

Medicines regulators in several major markets have issued a mix of approvals, safety communications, supply notices, enforcement actions and procedural updates over the past week.

The latest round-up includes the US Food and Drug Administration (FDA) approval of Trutakna, safety updates from the European Medicines Agency (EMA), a UK approval from the Medicines and Healthcare products Regulatory Agency (MHRA), and further official updates from Japan, Canada, Switzerland, Australia, Brazil, France, India and Italy. The table below summarizes official human medicines regulatory updates from the past seven days.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical